41 results on '"Contractor, Kaiyumars"'
Search Results
2. Supplementary Tables 1-4 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
3. Supplementary Data from Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab
4. Supplementary Table 1 from [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
5. Supplementary Figure 4 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
6. Supplementary Figure 6 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
7. Supplementary Figure 1 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
8. Supplementary Figure 2 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
9. Supplementary Figure 3 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
10. Supplementary Data from Altered Tissue 3′-Deoxy-3′-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography
11. Supplementary Table 2 from [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
12. Supplementary Figure 5 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
13. Supplementary Figure Legends 1-7 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
14. Supplementary Table 3 from [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
15. Supplementary Figure 7 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
16. Advances in Benign Breast Diseases
17. Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data
18. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer
19. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [18F] 3´-deoxy-3´-fluorothymidine PET: a pilot study
20. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography
21. P117. TIGR Matrix synthetic long-term resorbable mesh for pre-pectoral and sub-pectoral implant based breast reconstruction: outcomes of two years’ practice
22. Male breast cancer: is the scenario changing
23. TIGR matrix for implant-based breast reconstruction – a long-term resorbable mesh
24. Development of a treatment pathway to improve quality of care in the management of breast abscess and mastitis
25. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy
26. Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
27. [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
28. Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab
29. Kinetic filtering of [18F]Fluorothymidine in positron emission tomography studies
30. Altered Tissue 3′-Deoxy-3′-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography
31. [11C]Choline Positron Emission Tomography in Estrogen Receptor–Positive Breast Cancer
32. Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis
33. Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
34. Male breast cancer: is the scenario changing
35. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
36. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
37. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
38. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer.
39. Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET.
40. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients.
41. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.